GLAXO BACKING GILEAD OLIGONUCLEOTIDE ANALOG R&D VENTURE
GLAXO BACKING GILEAD OLIGONUCLEOTIDE ANALOG R&D VENTURE with$20 mil. over a period of up to five years. Announced July 26, the anticancer R&D collaborative agreement gives Glaxo an equity position in the privately-held Gilead Sciences of approximately 10%. The agreement focuses on anti-cancer applications of genetic targeting. Foster City, Calif.-based Gilead says the first part of the project will center on the creation of oligonucleotide analogs. Genetic targeting is an enabling technology that allows the identification of harmful genes. Once identified, rational drug design offers a potential tool for creating blockers to those harmful genes. Oligonucleotide analogs, "small DNA-like molecules," are one of the synthetic "antisense" substances that can be made to bind to a specific DNA or RNA sequence. The actual research collaboration will involve Gilead scientists in California and researchers at Glaxo Group Research headquarters in Greenford, U.K. While citing the "immense potential" of genetic targeting, Glaxo pointed out that it would take "several years before we know whether genetic targeting will lead to safe and effective medicines." Officials from Glaxo and Gilead said that the agreement was the first of its kind for both companies. Gilead was founded in August 1987; the company's President and CEO is Michael Riordan. The company has raised more than $12 mil. from venture capitalists to date, excluding the Glaxo investment. In addition to the new Glaxo agreement, Gilead has scientific collaborations with Stanford University, the University of California at San Francisco Medical Center and the University of California at Berkeley.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth